Smith & Nephew plc vs Synopsys, Inc. — how do they compare? Smith & Nephew plc trades at $30.05 (market cap $12.54B), while Synopsys, Inc. trades at $411.99 (market cap $78.68B). The key difference: Synopsys, Inc. is far larger — about 6.3× Smith & Nephew plc's market cap, and Smith & Nephew plc pays a 2.65% dividend while Synopsys, Inc. pays none. Which is the better fit depends on your goals.
| SNN | SNPS | |
|---|---|---|
Market Cap | $12.54B | $78.68B |
Sector | Health | Technology |
52-Week High | $38.70 | $625.80 |
52-Week Low | $28.73 | $372.33 |
Enterprise Value | $15.57B | $87.04B |
Dividend Yield | 2.65% | — |
Trailing returns across standard periods
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →